CAR T-Cell Trial in Rheumatoid Arthritis Starts Off Strong

(MedPage Today) -- LONDON -- Most patients with super-refractory, seropositive rheumatoid arthritis (RA) responded well to chimeric antigen receptor (CAR) T-cell therapy in the first part of an ongoing phase I/II trial, a researcher reported...
Source
MedPage Today
Opens original article in a new tab



